Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine

REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., – May 16, 2022 – Kriya Ther­a­peu­tics, Inc., a fully integrated gene therapy company pioneering novel tech­nolo­gies and ther­a­peu­tics, today announced a $270 Million Series C financing. The financing was led by Patient Square Capital, with par­tic­i­pa­tion from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors. Proceeds from this financing will support the advancement of Kriya’s pipeline and continued scaling of its engineering, man­u­fac­tur­ing, and com­pu­ta­tion­al platforms.

Kriya has established an ecosystem for delivering best-in-class tech­nolo­gies and medicines in gene therapy, with core business units in technology, man­u­fac­tur­ing, R&D, and ther­a­peu­tics. By leveraging its proprietary com­pu­ta­tion­al platform, in-house man­u­fac­tur­ing infra­struc­ture, and rational design toolkit, the company is uniquely positioned to bring potentially trans­for­ma­tive gene therapies to a broad range of diseases.

“We believe gene therapy has the potential to redefine medicine over the next decade. However, the field has been constrained by tech­no­log­i­cal and operational challenges that make it difficult and expensive to deliver new products,” said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya. ​“Kriya was founded to address the primary problems limiting the field, and I am proud of the progress we have made to date. This financing will support our continued growth as we advance our diverse pipeline into the clinic and further scale our core platforms, to achieve our ultimate vision of expanding the reach and unlocking the full potential of gene therapy as a modality.”

In recent months, Kriya has achieved several milestones across key parts of its business. The company sig­nif­i­cant­ly expanded its pipeline through its internal R&D efforts, as well as through acqui­si­tions and part­ner­ships with leading companies and academic insti­tu­tions. In addition, Kriya oper­a­tional­ized its state-of-the-art, scalable GMP man­u­fac­tur­ing infra­struc­ture in Research Triangle Park, North Carolina to support in-house production from early through late phase development. This infra­struc­ture also empowers the development and imple­men­ta­tion of novel tech­nolo­gies and processes that enable consistent, large-scale man­u­fac­tur­ing. Kriya has also scaled SIRVE™, its machine learning-enabled technology and cloud computing archi­tec­ture, to support the integration of large datasets generated by the company’s high throughput screening, next generation sequencing, and algorithmic data mining platforms.

“Kriya has made tremendous strides over the past few years, attracting world-class talent, expanding its pipeline, and scaling the infra­struc­ture necessary to unlock the full potential of gene therapy,” said Jim Momtazee, Managing Partner of Patient Square Capital and Kriya Board Member. ​“We believe the company has the potential to be the clear leader in the evolving gene therapy field, consistent with Patient Square Capital’s focus to build and support category leading companies in health care.”

About Kriya
Kriya is a fully integrated gene therapy company on a mission to rev­o­lu­tion­ize how gene therapies are designed, developed, and man­u­fac­tured – with a goal of improving speed to market and reducing cost. The company leverages its proprietary com­pu­ta­tion­al engine, in-house man­u­fac­tur­ing infra­struc­ture, and integrated design platform to engineer products with the potential to transform the treatment of a broad range of diseases. Kriya’s team includes scientific pioneers with decades of experience in product development, complex man­u­fac­tur­ing, and com­pu­ta­tion­al engineering.

The company has established an ecosystem for delivering best-in-class tech­nolo­gies and medicines, with core business units in technology, man­u­fac­tur­ing, R&D, and ther­a­peu­tics. Kriya’s product pipeline addresses diseases of high unmet need with therapeutic area divisions in oph­thal­mol­o­gy, oncology, rare disease, and chronic disease, each led by industry veterans with a track record of advancing products from concept through com­mer­cial­iza­tion. Built upon this foundation, Kriya achieves the scale needed to drive trans­for­ma­tion­al improve­ments in the engineering, production, and translation of gene therapies. For more information, please visit www​.kriyatx​.com and follow on LinkedIn.

Contact
Danielle Cantey
Canale Com­mu­ni­ca­tions
danielle.​cantey@​canalecomm.​com
(619) 826‑4657